A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery

Exclusion Criteria

• •Pregnant and nursing women
• •Men or women of childbearing potential who are unwilling to employ adequate contraception for up to 6 months following the completion of PCV.
• •Received any prior radiation therapy or chemotherapy for any CNS neoplasm.
• •Co-morbid systemic illnesses or other severe concurrent disease which would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
• •Concomitant serious immunocompromised status (other than that related to concomitant steroids).
• •Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.
• •Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm (except specific inhibitors of IDH)
• •Other active malignancy within 5 years of registration. Exceptions: Non-melanotic skin cancer or carcinoma-in-situ of the cervix.
• •Contra-indication to CCNU: hypersensitivity to CCNU, wheat allergy, association to yellow fever vaccin
• •Contra-indication to Procarbazine: severe renal failure, severe hepatic failure, hypersensitivity to procarbazine, association to yellow fever vaccin
• •Contra-indication to Vincristine: hypersensitivity to vincristine, neuromuscular disorder (for example demyelinating Charcot-Mary Tooth neuropathy), severe renal failure, severe hepatic failure.
• •Not depending from the french system of health assurance